Latest Board Changes News

Cannindah Resources has secured $4.5 million through a fully underwritten entitlement offer to accelerate drilling at its Mt Cannindah copper-gold project, unveiling promising new high-grade porphyry targets that could reshape its resource profile.

NSX Limited has been fully acquired by a Canadian entity, leading to the suspension and imminent delisting of its shares from the ASX. A new non-executive director has been nominated as part of the transition.

Johns Lyng Group has officially been acquired by Sherwood BidCo, controlled by Pacific Equity Partners, with shareholders receiving $4.00 per share or equity in the new entity. The company will be delisted from the ASX on October 24, marking a new chapter under private ownership.

Spectur Limited has successfully raised $2.3 million through a premium-priced placement to fast-track its AI Cloud Platform and sovereign cloud capabilities, alongside notable board changes ahead of its AGM.

Highfield Resources has secured a A$10 million convertible note investment from existing strategic shareholders following the collapse of a proposed strategic transaction with China Minmetals and Yankuang Energy. The company also received renewed institutional backing from the Government of Navarra for its flagship Muga Potash Project.

Anatara Lifesciences reports steady progress in its anti-obesity pre-clinical studies with results expected by year-end, while preparing its GaRP gastrointestinal health data for publication amid ongoing commercial talks. The company also announces a key board appointment and a $1.2 million capital raise.

Insurance Australia Group (IAG) reported strong FY25 results and upgraded its FY26 guidance, reflecting the completed RACQ acquisition and ongoing strategic growth initiatives.

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Cochlear Limited reports steady FY25 financials alongside the launch of its innovative Nucleus Nexa cochlear implant system, setting the stage for projected double-digit profit growth in FY26.

Acumentis delivered a 3.4% revenue increase to $58.1 million at its 2025 AGM, highlighting diversification and a positive outlook for FY26 amid easing inflation and expected rate cuts.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

Tasman Resources has raised $2 million through a two-tranche placement to fund a promising drilling campaign at Parkinson Dam and broaden its project portfolio, alongside appointing a new director to steer its strategic ambitions.